Dual targeting of CDK4 and ARK5 using a novel kinase inhibitor ON123300 is effective in vitro and in vivo in Multiple Myeloma

被引：0

作者：

Perumal, Deepak ^{[1
]}

Thirukonda, Venu ^{[2
]}

Jiang, Zewei ^{[3
]}

Leshchenko, Violetta V. ^{[1
]}

Kuo, Pei-Yu ^{[1
]}

Shahnaz, Samira ^{[4
]}

Rubel, Jennifer ^{[1
]}

Zhang, Weijia ^{[1
]}

Cho, Hearn Jay ^{[1
]}

Reddy, M. V. Ramana ^{[1
]}

Reddy, E. Premkumar ^{[1
]}

Parekh, Samir ^{[1
]}

机构：

[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[2] Billings Clin Canc Ctr, Billings, MT USA

[3] Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10467 USA

[4] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA

来源：

CANCER RESEARCH | 2014年 / 74卷 / 19期

关键词：

D O I：

10.1158/1538-7445.AM2014-1324

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1324

引用

页数：2

共 37 条

[31] Absorption of CH330331, A Novel 4-Anilinoquinazoline Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase: Comparative Studies using In Vitro, In Situ and In Vivo Models
Sun, Haiyan
Bi, Huichang
Huang, Min
Liu, Dong
Qin, Zhenyu
BIOPHARMACEUTICS & DRUG DISPOSITION, 2010, 31 (8-9) : 486 - 494
[32] Synthesis, in vitro and in vivo biological evaluation of novel dual compounds targeting both acetylcholinesterase and serotonergic 5-HT4 receptors with potential interest in the treatment of Alzheimer's disease
Rochais, Christophe
Lecoutey, Cedric
Lalut, Julien
Davis, Audrey
Duval, Emilie
Gaven, Florence
Largilliere, Stacy
Nee, Gerald
Corvaisier, Sophie
Santos, Jana Sopkova de Oliveira
Since, Marc
Freret, Thomas
Legrand, Romain
Callizot, Noelle
Claeysen, Sylvie
Boulouard, Michel
Dallemagne, Patrick
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 280
[33] In vitro and in vivo pharmacological characterization of BM-613[N-n-pentyl-N′-[2-(4′-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist
Hanson, J
Rolin, S
Reynaud, D
Qiao, N
Kelley, LP
Reid, HM
Valentin, FO
Tippins, J
Kinsella, BT
Masereel, B
Pace-Asciak, C
Pirotte, B
Dognê, JM
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 313 (01): : 293 - 301
[34] A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo
von Strandmann, EP
Hansen, HP
Reiners, KS
Schnell, R
Borchmann, P
Merkert, S
Simhadri, VR
Draube, A
Reiser, M
Purr, I
Hallek, M
Engert, A
BLOOD, 2006, 107 (05) : 1955 - 1962
[35] Discovery of &ITN&IT1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7&ITH&IT-pyrrolo[2,3-&ITd&IT]pyrimidin-2-yl)amino)phenyl)-&ITN&IT8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase 1 (HDAC1) against Malignant Cancer
Li, Yongtao
Luo, Xiaohe
Guo, Qingxiang
Nie, Yongwei
Wang, Tianqi
Zhang, Chao
Huang, Zhi
Wang, Xin
Liu, Yanhua
Chen, Yanan
Zheng, Jianyu
Yang, Shengyong
Fan, Yan
Xiang, Rong
JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (07) : 3166 - 3192
[36] ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties.: II.: In vivo characterization in the rat
Kowaluk, EA
Mikusa, J
Wismer, CT
Zhu, CZ
Schweitzer, E
Lynch, JJ
Lee, CH
Jiang, MQ
Bhagwat, SS
Gomtsyan, A
McKie, J
Cox, BF
Polakowski, J
Reinhart, G
Williams, M
Jarvis, MF
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2000, 295 (03): : 1165 - 1174
[37] ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties:: I.: In vitro characterization and acute antinociceptive effects in the mouse
Jarvis, MF
Yu, HX
Kohlhaas, K
Alexander, K
Lee, CH
Jiang, MQ
Bhagwat, SS
Williams, M
Kowaluk, EA
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2000, 295 (03): : 1156 - 1164

← 1 2 3 4 →